Automate Your Wheel Strategy on PASG
With Tiblio's Option Bot, you can configure your own wheel strategy including PASG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PASG
- Rev/Share 0.0
- Book/Share 0.752
- PB 0.5864
- Debt/Equity 0.5377
- CurrentRatio 3.7402
- ROIC -0.958
- MktCap 27407400.0
- FreeCF/Share -0.6908
- PFCF -0.6387
- PE -0.4316
- Debt/Assets 0.292
- DivYield 0
- ROE -0.9359
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | PASG | Rodman & Renshaw | -- | Buy | -- | $7 | Sept. 3, 2024 |
News
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), …
Read More
Passage Bio to Participate in Upcoming Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Read More
About Passage Bio, Inc. (PASG)
- IPO Date 2020-02-28
- Website https://www.passagebio.com
- Industry Biotechnology
- CEO William Chou
- Employees 60